Skip to content

Effect of intravenous esketamine on lung injury in patients undergoing thoracoscopic surgery under single-lung ventilation

Effect of intravenous esketamine on lung injury in patients undergoing thoracoscopic surgery under single-lung ventilation - Esketamine lung protection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093592
Enrollment
Unknown
Registered
2024-12-09
Start date
2025-01-01
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung injury

Interventions

Esketamine group:Esketamine 0.5mg/kg was inducted intravenously in the esketamine anesthesia group and 0.15mg/kg/h in the esketamine group during the operation.
Control group:The same volume of normal saline is infused

Sponsors

The First Affiliated Hospital of Henan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age 30-75 years old, male or female; (2) United States College of Anesthesiologists (ASA) Physical Status Grading System Level II-III; (3) Body mass index (BMI) 19~28 kg/m^2; (4) Elective thoracoscopic radical lung cancer resection

Exclusion criteria

Exclusion criteria: (1) History of preoperative use of radiotherapy, chemotherapy, anti-inflammatory drugs, hormonal drugs and thoracic organ surgery; (2) Patients with severe COPD, interstitial lung disease, bullae, or extremely low preoperative lung function (FEV1% 30 mmHg or SPO2 <90% during intraoperative single-lung ventilation (OLV);

Design outcomes

Primary

MeasureTime frame
Oxygenation index;

Secondary

MeasureTime frame
Alveolar-arterial partial pressure difference;Respiratory index;Lung dynamic compliance ;TNF-a, IL-6, IL-10 concentrations;Mean arterial pressure;Incidence of adverse reactions;

Countries

China

Contacts

Public ContactFu Chunyan

The First Affiliated Hospital of Henan University

2363231984@qq.com+86 166 2750 3706

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026